证券代码： 300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------|------------------------------------------|--------------| | 投资者关系活动 \n类别 | □特定对象调研 □分析师会议 \n□媒体采访 \n□新闻发布会 □路演活动 \n□现场参观 | □业绩说明会 \n√ 其他 电话会议/线上会议 | | | | 安信基金 | 华富基金 | 泰达宏利 | | | Boyu Capital | 华能贵诚信托 | 泰康基金 | | | 宝弘资产 | 华泰柏瑞 | 泰信基金 | | | 宝盈基金 | 华夏基金 | 天风证券 | | | 博时基金 | 华夏久盈 | 天风资管 | | | 博远基金 | 华银基金 | 天弘基金 | | | 渤海汇金 | 怀 ...

证券代码： 300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |----------------|------------------------|--------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 安信证券 马帅 | | | 人员姓名 | 安信证券 李奔 | | | 时间 | 2021 年 1 月 7 | 日 | | | | | | 地点 | 迪瑞医疗公司会议室 | | | 上市公司接待 | | 董事会秘书安国柱 华润资本投资部姜仁伟、王磊 | | 人员姓名 | 1.迪瑞医疗在 | 2020 年完成了控制权的变更，实现了股权多元 | | 投资者关系活动 | | 化的战略目标，请介绍一下当前公司的股权分布情况？ | | ...

证券代码： 300396 证券简称：迪瑞医疗 编号：2021-003 | --- | --- | --- | |----------------|----------------------|------------------------------| | | □ | 特定对象调研 ■分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 胡博新、李勇东兴证券 | | | 人员姓名 | 张小兵 | 江苏瑞华投资控股集团有限公司 | | | 刘钰 繁星资本 | | | | 江錫九 | 躍馬資本有限公司 | | | 罗娟 | 广东恒昇基金管理有限公司 | | | 樊景扬 国联证券 | | | | 徐成城 国泰投研 | | | | 孙关世裿 | 上海枫池资产管理有限公司 | | | 刘俊 中海基金 | | | | 吕科 | 深圳亘泰投资管理有限公司 | | | 雍加兴 | 东莞证券股份有限公司（自营） | | | 赵勇 中再资产 | | 迪瑞医疗科技股份有限公司 投资 ...

证券代码： 300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2021-004 | --- | --- | --- | |----------------|------------------------|--------------------------| | | □ | 特定对象调研 ■分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | | 兴业证券 李昶霖 | | | | 渤海汇金证券资产 | 纪钢 | | | 长城财富资管 | 胡纪元 | | | 民生信托 景莹 | | | | 永安国富 张文平 | | | 参与单位名称及 | 前海太行资管 | 张家义 | | 人员姓名 | 前海太行资管 | 徐平龙 | | | 华安资产 房晓 | | | | 合众资管 金妍 | | | | 碧云资本 周伊莎 | | | | 光大资管 徐德仁 | | | | 中金公司 谢秉稚 | | | --- | --- | |----------------|- ...

证券代码： 300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | |----------------|-----------------------------|---------------------------------------------------------| | | ■ 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | | 东兴证券 胡博新、李勇 | 禾泰投资 陈宁 | | | 君创基金 刘寅刚 | 摩根士丹利华鑫基金 张伟 | | 参与单位名称及 | 上海软盛 叶希 | 上海鑫绰 武秋耀 | | 人员姓名 | 上海照友 夏雨、邬子轩 | 上海证券报 刘铎 | | | 尚景汇 邵尔琛 | 证券日报 陈新淼 | | | 中泰证券 李建 | 中信建投 罗兴 | | 时间 | 2021 年 1 月 4 日 | | | 地点 | 迪瑞医疗公司会议室 | | ...

证券代码： 300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | |----------------|--------------------------------|-------------| | | □特定对象调研 ■分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | | 东北证券 | | | | 国泰君安证券 | | | | 黑森投资 | | | | 工银瑞信基金管理有限公司 | | | | 海螺创业 | | | | 上海顶天投资 | | | | 深圳柏杨投资管理有限公司 | | | | 北京中港融鑫资产管理有限公司 | | | 参与单位名称及 | 浙江同花顺云软件有限公司 | | | 人员姓名 | 深圳进门财经科技股份有限公司 | | | | 富国基金管理有限公司 | | | | 华宸未来基金管理有限公司 | | | | 上海人寿保险股份有限公司 | | | | 上海亘通投资管理有 ...

证券代码： 300396 证券简称：迪瑞医疗 编号：2022-003 迪瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|-----------------------------------------------|---------------------------------------| | | □特定对象调研 | 分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 电话会议/线上会议 | | | | 安信基金 陈少波 | 平安基金 刘杰 | | | 博时基金 张弘 | 青岛晟庄私募基金 张海峰 | | | 创金合信基金 王鑫 | 上海和谐汇资产 陈凯 | | | 长盛基金 周思聪 | 上海冲积资产 张智聪 | | | 大成基金 郑少芳 | 上海东方证券资产 徐宏 江琦 刘中群 | | | 东北证券 刘宇腾 余丹 苑 温中朝 王雷 | 上海照友投资 邬子轩 | | | | | | | 东吴基金 吴佳歆 | 上海睿扬投资 王世超 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥287,550,505.90, representing a 33.35% increase compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥62,047,470.73, up 34.11% year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥57,985,117.80, reflecting a 27.25% increase from the previous year[7] - The company's basic earnings per share for Q3 2022 was ¥0.2295, which is a 35.96% increase compared to the same period last year[7] - Total operating revenue for the third quarter reached ¥802,355,021.58, an increase of 26.7% compared to ¥633,262,601.15 in the same period last year[43] - Net profit for the quarter was ¥194,660,648.50, compared to ¥156,184,874.19 in the previous year, representing a growth of 24.6%[47] - Basic and diluted earnings per share for the period were both CNY 0.7144, compared to CNY 0.5666 in the previous period, reflecting an increase of 26.1%[50] - The total comprehensive income for the period attributable to the parent company was CNY 197,075,492.47, an increase from CNY 156,120,603.29 in the previous period, representing a growth of approximately 26.3%[50] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,750,511,075.31, a 15.78% increase from the end of the previous year[7] - Total assets as of the end of the reporting period were ¥2,750,511,075.31, compared to ¥2,375,626,201.07 at the same time last year, marking an increase of 15.7%[43] - Total liabilities increased to ¥825,700,802.19 from ¥499,277,247.97, reflecting a significant rise of 65.2%[43] - The company's equity attributable to shareholders reached ¥1,924,808,986.48, up from ¥1,876,348,953.10, a growth of 2.6%[43] Cash Flow - Cash flow from operating activities showed a net outflow of ¥11,014,422.84, a significant decline of 125.45% year-on-year[7] - The net cash flow from operating activities decreased by 125.45% to -1,101.44 million RMB compared to 4,328.19 million RMB in the same period last year, primarily due to increased cash payments for inventory procurement[16] - Cash inflow from operating activities totaled CNY 716,564,136.21, up from CNY 623,975,763.80 in the previous period, indicating a growth of about 14.9%[51] - Cash outflow from operating activities was CNY 727,578,559.05, compared to CNY 580,693,887.47 in the previous period, resulting in a net cash flow from operating activities of CNY -11,014,422.84[51] - The net increase in cash and cash equivalents for the period was CNY 228,825,164.50, compared to CNY 42,394,752.45 in the previous period, indicating a significant improvement[51] Investments and Financing - The net cash flow from investing activities increased by 170.13% to 23,462.77 million RMB from 8,685.79 million RMB, mainly due to the redemption of matured financial products during the reporting period[16] - Cash inflow from investment activities reached CNY 1,310,996,078.84, significantly higher than CNY 92,548,750.00 in the previous period, marking an increase of approximately 1,418.5%[51] - Cash outflow from investment activities was CNY 1,076,368,340.79, leading to a net cash flow from investment activities of CNY 234,627,738.05[51] - The net cash flow from financing activities improved by 97.14% to -247.27 million RMB from -8,633.24 million RMB, attributed to an increase in bank loans received and a decrease in bank loans repaid[16] - Cash inflow from financing activities amounted to CNY 165,642,440.02, compared to CNY 102,516,650.00 in the previous period, reflecting a growth of about 61.5%[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,079, with no ordinary shares held[17] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 28.08% of the shares, amounting to 77,288,400 shares, with 61,057,836 shares pledged[20] - The company reported a total of 26,442,170 restricted shares at the beginning of the period, with 2,684,350 shares released from restrictions during the period[26] - The company completed the repurchase and cancellation of 649,900 restricted stocks, reducing its total share capital from ¥275,894,600 to ¥275,244,700[34] - The company granted 2.8871 million restricted stocks to 91 incentive targets on August 29, 2022, with the listing date set for September 19, 2022[36] Strategic Initiatives - The company is implementing a strategic shift from research-driven to sales-driven operations, leveraging national policies supporting the medical device industry[28] - The company has executed two phases of equity incentives to align shareholder interests with the core management team, ensuring stable growth and development[28] - The company is positioned for steady and rapid development, capitalizing on policy dividends and strategic development momentum[28] - The company has actively expanded its product lines, focusing on high-end products such as urine analysis and biochemical immunoassay lines, which have gained recognition from end customers[29] - The company plans to establish a postdoctoral research workstation to enhance its R&D capabilities in the in vitro diagnostic field[29] - The company has emphasized the importance of patent protection to enhance its core competitiveness and promote technological innovation[29] - The company is committed to continuous investment and technological exploration in the in vitro diagnostic field to improve product performance and expand its product coverage[29] Research and Development - Research and development expenses increased to ¥75,481,019.27, up from ¥65,565,579.46, indicating a rise of 15.5% year-over-year[47] - The company has completed 201 patents, including 115 invention patents, and has been recognized as a "National Intellectual Property Demonstration Enterprise" for 2022[29] Miscellaneous - The impact of exchange rate changes on cash and cash equivalents resulted in a gain of 768.45 million RMB, a significant turnaround from a loss of 141.26 million RMB in the previous year, reflecting favorable exchange rate movements[16] - The company has revised its performance assessment requirements due to external factors such as the pandemic and national healthcare cost control policies[34] - The report for the third quarter was not audited[55]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥514,804,515.68, representing a 23.27% increase compared to ¥417,624,110.18 in the same period last year[29]. - The net profit attributable to shareholders of the listed company was ¥132,617,507.94, up 20.65% from ¥109,919,173.47 in the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥126,374,514.79, an increase of 18.20% compared to ¥106,916,504.55 in the same period last year[29]. - The basic earnings per share for the reporting period was ¥0.4864, reflecting a growth of 22.27% from ¥0.3978 in the previous year[29]. - The total assets at the end of the reporting period were ¥2,523,650,414.51, which is a 6.23% increase from ¥2,375,626,201.07 at the end of the previous year[29]. - The net assets attributable to shareholders of the listed company were ¥1,860,009,949.48, showing a slight decrease of 0.87% from ¥1,876,348,953.10 at the end of the previous year[29]. - The company reported a net cash flow from operating activities of -¥1,026,318.30, a significant decline of 104.01% compared to ¥25,612,479.02 in the same period last year[29]. - The weighted average return on equity for the reporting period was 7.00%, an increase of 0.48% from 6.52% in the previous year[29]. - The gross margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[62]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a 20% year-over-year growth[62]. Market Expansion and Strategy - The company operates in the in vitro diagnostic (IVD) industry, which is experiencing rapid growth due to increasing demand and technological advancements, with a projected global market size of $79.6 billion by 2024, capturing 13.4% of the medical device market[39]. - The company has established a sales and service network in over 120 countries and regions globally, leveraging local teams for market expansion[50]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[118]. - Market expansion efforts include entering three new provinces in China, aiming to increase market share by 10% in these regions by the end of 2023[62]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a target of completing at least one acquisition by the end of 2022[62]. - The company is actively pursuing opportunities for market expansion and potential acquisitions to strengthen its competitive position in the healthcare industry[68]. - The company is focusing on enhancing its online sales channels, aiming for a 30% increase in online sales by the end of 2022[62]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[124]. Product Development and Innovation - The company has launched new products such as gynecological secretion analysis systems and coagulation analysis systems, which have gained market recognition and are expected to enhance competitiveness[39]. - The company has introduced a new line of rapid testing kits, which are anticipated to capture a 10% market share within the first year of launch[76]. - The company is committed to ongoing research and development to innovate and improve its diagnostic technologies[3][4][5][6][7][8][9][10][11][12][13]. - The company has launched multiple diagnostic reagent kits, including growth hormone and collagen type IV detection kits, approved for use until September 2024[228][230]. - The company is actively developing new products, including a series of immunoassay kits for various biomarkers, enhancing its product portfolio[229][234]. - The company has introduced various immunological test kits, including Rheumatoid Factor and C-Reactive Protein test kits, with registration valid until July 31, 2027[141][147]. - The company has developed a series of reagent kits for quantitative detection of various substances in human serum or plasma, including total bilirubin and glucose, with some products having registration valid until July 2027[109][114]. - The company is focusing on research and development of new technologies to enhance its diagnostic capabilities and meet evolving market demands[109]. Quality Control and Compliance - The company has established a strong product quality management system, achieving ISO9001 and ISO13485 certifications, with most medical testing products obtaining CE certification and some receiving FDA approval[155]. - The company emphasizes the importance of quality control in clinical diagnostics, with products aimed at ensuring the accuracy and repeatability of test results[104]. - The company is committed to maintaining high standards in product quality and compliance with regulatory requirements, ensuring customer trust and satisfaction[109]. - The company has implemented quality control measures such as DFMEA and QCC to further improve its quality management system[155]. - The company is focused on maintaining compliance with regulatory standards to ensure the longevity of its product registrations[83]. Challenges and Risks - The company faces risks from strict industry regulations and policies, which may require adjustments to its marketing system[185]. - The company acknowledges the risk of intensified market competition in the in vitro diagnostics sector and emphasizes the need for innovation and product development[189]. - The company is expanding its overseas market presence, but faces risks from international political and economic uncertainties, as well as exchange rate fluctuations[192]. - The ongoing uncertainty of the COVID-19 pandemic continues to impact the company's overall operations, prompting the company to optimize production strategies accordingly[194]. Future Outlook - Future guidance indicates a projected revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion strategies[62]. - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30% compared to the first half[126]. - The company aims to achieve a net profit margin of 15% by the end of 2022, up from 12% in 2021, driven by operational efficiencies and cost reductions[126]. - The company has outlined a positive outlook for the next quarter, projecting a revenue growth of 25%[146].

Financial Performance - The company's operating revenue for 2021 was ¥905,795,040.28, a decrease of 3.35% compared to ¥937,235,915.34 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥209,948,414.77, down 21.39% from ¥267,071,664.29 in the previous year[19]. - The net cash flow from operating activities decreased by 28.96% to ¥167,412,927.13 in 2021, compared to ¥235,647,142.87 in 2020[19]. - Basic earnings per share for 2021 were ¥0.76, a decline of 21.65% from ¥0.97 in 2020[19]. - The total revenue for 2021 was approximately ¥905.80 million, a decrease of 3.35% compared to ¥937.24 million in 2020[56]. - Net profit attributable to shareholders was CNY 209.95 million, down 21.39% year-on-year, primarily due to the divestment of Ningbo Ruiyuan subsidiary[50]. - Excluding the impact of Ningbo Ruiyuan, the company's revenue grew by 11.60% year-on-year, reaching CNY 906 million, with net profit increasing by 2.31% to CNY 183 million[50]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% year-over-year[42]. - The company reported a significant increase in revenue, achieving a total of 1.6 billion RMB in 2021, representing a year-over-year growth of 25%[87]. Assets and Liabilities - Total assets at the end of 2021 increased by 17.40% to ¥2,375,626,201.07, compared to ¥2,023,448,189.59 at the end of 2020[19]. - The net assets attributable to shareholders rose by 13.41% to ¥1,876,348,953.10 at the end of 2021, up from ¥1,654,500,366.12 in 2020[19]. - Cash and cash equivalents decreased to ¥460.70 million, representing 19.39% of total assets, down from 33.98% at the beginning of the year, primarily due to investments in financial products[109]. - Accounts receivable increased slightly to ¥128.53 million, maintaining a stable proportion of 5.41% of total assets[109]. - Inventory rose to ¥237.30 million, accounting for 9.99% of total assets, a decrease of 0.80% compared to the previous year[109]. - Long-term equity investments grew to ¥400.36 million, making up 16.85% of total assets, down by 1.61%[109]. - Short-term borrowings remained at ¥150.00 million, accounting for 6.31% of total assets, a decrease of 1.10%[109]. Market Position and Strategy - The company operates in the in vitro diagnostics (IVD) industry, which is expected to reach a global market size of 79.6 billion by 2024, capturing 13.4% of the medical device market[29]. - The medical device market is projected to grow at a compound annual growth rate (CAGR) of 5.6%, reaching 59.45 billion by 2024[29]. - The company is positioned to benefit from increasing healthcare awareness and demand due to factors such as population aging and the implementation of health policies[29]. - Recent government policies aim to enhance the development of high-end medical devices and improve the healthcare service system, which may positively impact the company's growth[30]. - The company is expected to expand its product offerings in response to the growing market for pregnancy-related diagnostic products[30]. - The company is focusing on expanding its market presence and improving product competitiveness through technological advancements and new product launches[70]. - The company aims to enhance its market share through the launch of new products and upgrades to existing products, such as the CS-2000 fully automated biochemical analyzer[70]. - The company plans to expand its market presence both domestically and internationally to achieve stable revenue growth[135]. - The company is strategically positioned to leverage its extensive product portfolio to capture growth opportunities in the healthcare sector[51][52]. Research and Development - The company has a robust R&D team of 367 personnel, accounting for 23% of the total workforce, with expertise across various fields including mechanics, optics, and clinical medicine[41]. - Research and development expenses increased by 10%, totaling 150 million RMB, reflecting the company's commitment to innovation[42]. - The company is focusing on R&D investment, with a product system gradually shifting towards intelligence and integration, including various automated analysis lines[46]. - The company is committed to continuous product development and technological innovation to meet market demands and enhance profitability[132]. - The company plans to invest 200 million RMB in research and development over the next two years to innovate new technologies in medical diagnostics[87]. - The company is actively pursuing research and development initiatives to improve the accuracy and efficiency of its diagnostic tests[90]. - The company is committed to maintaining high standards in product quality and regulatory compliance across its offerings[84]. Product Development and Innovation - The company has developed numerous high-end medical devices, including a fully automated gynecological secretion analysis system that enhances accuracy and efficiency in testing[40]. - The company launched several new products, including the GD-S120 fully automated gynecological analyzer and the BF-7200 fully automated blood cell analyzer, enhancing its product portfolio[70]. - The company has successfully launched new products, including a coagulation analysis system, which is expected to drive reagent sales and enhance competitiveness[39]. - The company is focused on expanding its product offerings in the medical device sector, particularly in diagnostics[72]. - The company has received regulatory approval for multiple medical testing kits, including those for measuring total bilirubin and pancreatic amylase, enhancing its product portfolio[76]. - The company is actively involved in the research and development of new testing technologies, as evidenced by the introduction of various enzyme activity measurement kits[84]. - The company aims to enhance its market presence through the continuous launch of innovative medical testing solutions[84]. - The company has received approval for multiple medical testing kits, including direct bilirubin and total bilirubin test kits, with a validity period until 2025[96]. Governance and Management - The company has established a governance structure that includes a shareholders' meeting, board of directors, and supervisory board, ensuring compliance with relevant regulations[140]. - The board consists of 9 members, including 3 independent directors, meeting legal and regulatory requirements[140]. - The company maintains complete independence in business, assets, and financial matters from its controlling shareholders[142]. - The company has a fully independent business system for research, production, and sales, without reliance on shareholders or related parties[143]. - The company has established independent decision-making and supervisory bodies in accordance with the Company Law and its articles of association[143]. - The company has established a structured remuneration scheme for its directors and senior management, which is subject to shareholder approval[166]. - The company has a diverse board with members holding various positions in other companies, indicating strong industry connections[164]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% driven by new product launches and market expansion[42]. - Future outlook indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by increased demand for its diagnostic products[91]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market share[94]. - The company is committed to continuous innovation, as evidenced by the registration of 12 new medical testing products in 2021[100]. - The company aims to enhance its market presence through the introduction of advanced diagnostic technologies and expanding its product offerings[100].